Clinical Trials List
2021-11-01 - 2022-08-29
Phase III
Recruiting6
ICD-10C61
Malignant neoplasm of prostate
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9185
Malignant neoplasm of prostate
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- - - Division of Urology
- Yu-Chieh Tsai Division of Hematology & Oncology
- KO-JEN LI Division of General Internal Medicine
- 劉詩彬 Division of Urology
- JIAN-HUA HONG Division of Urology
- FU-JEN HSUEH Division of Hematology & Oncology
- YU-CHUAN LU Division of Urology
- JHE-CYUAN GUO Division of Hematology & Oncology
- CHING-CHU LU Division of Nuclear Medicine
- CHUNG-HSIN CHEN Division of Urology
- Ying-Chun Shen Division of Hematology & Oncology
- YEN-HENG LIN Division of Radiology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yung-Chang Lin Division of Hematology & Oncology
- Rita cheng Division of Hematology & Oncology
- I-hung Shao Division of Hematology & Oncology
- Kung-Chu Ho Division of Nuclear Medicine
- PO-HUNG LIN Division of Hematology & Oncology
- 張境夫 Division of Hematology & Oncology
- Hong-Cheng Gan Division of Hematology & Oncology
- 陳東藝 Division of Cardiovascular Diseases
- 張鈞弼 Division of Radiology
- 黃文冠 Division of Hematology & Oncology
- 林柏宏 Division of Hematology & Oncology
- 黃亮鋼 Division of Hematology & Oncology
- Jing-Ren Tseng Division of Nuclear Medicine
- Po-Jung Su Division of Hematology & Oncology
- Kai-Jie Yu Division of Hematology & Oncology
- Yuan-Cheng Chu Division of Hematology & Oncology
- Feng-Yuan Liu Division of Nuclear Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chi-Ping Huang Division of Urology
- Chao-Hsiang Chang Division of Urology
- Wei-Ching Lin Division of Radiology
- Hsi-Chin Wu Division of Urology
- Che-Hung Lin Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 賴香蘭 Division of Hematology & Oncology
- 鄭元佐 Division of Urology
- 林偉雄 Division of Radiology
- 吳佳哲 Division of Hematology & Oncology
- 康智雄 Division of Urology
- 常景棣 Division of Radiology
- 陳彥豪 Division of Hematology & Oncology
- 郭明濬 Division of Hematology & Oncology
- 羅浩倫 Division of Urology
- 陳彥仰 Division of Hematology & Oncology
- 黃詩喻 Division of Hematology & Oncology
- 王弘仁 Division of Urology
- 徐健欽 Division of Nuclear Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yen-Hwa Chang Division of Urology
- 陳威任 Division of Urology
- Tzu-Ping Lin Division of Urology
- Tzu-Hao Huang Division of Urology
- 沈書慧 Division of Radiology
- Yi-Hsiu Huang Division of Urology
- Tzu-chun Wei Division of Urology
- Chien-Hsin Ting Division of Nuclear Medicine
- Chih-Chieh Lin Division of Urology
- I-Shen Huang Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
25 participants
-
Global
800 participants
